REPLIGEN CORP Deferred Tax and Other Liabilities, Noncurrent
REPLIGEN CORP (RGEN) had Deferred Tax and Other Liabilities, Noncurrent of $16.78 million as of 2026-06-30, per its 10-Q filed 2026-07-29.
Financial Statements › Notes
us-gaap:DeferredTaxAndOtherLiabilitiesNoncurrent · last filed 2026-07-29
- 2026-06-30: Deferred Tax and Other Liabilities, Noncurrent $16.78M.
- 2026-03-31: Deferred Tax and Other Liabilities, Noncurrent $15.02M.
- 2025-12-31: Deferred Tax and Other Liabilities, Noncurrent $22.50M.
- 2025-09-30: Deferred Tax and Other Liabilities, Noncurrent $20.14M.
| Period end | Deferred Tax and Other Liabilities, Noncurrent | Deferred Tax and Other Liabilities, Noncurrent as first filed |
|---|---|---|
| 2026-06-30 | $16.78M 10-Q · filed 2026-07-29 | |
| 2026-03-31 | $15.02M 10-Q · filed 2026-05-06 | |
| 2025-12-31 | $22.50M 10-Q · filed 2026-07-29 | |
| 2025-09-30 | $20.14M 10-Q · filed 2025-11-04 | |
| 2025-06-30 | $23.33M 10-Q · filed 2025-08-07 | |
| 2025-03-31 | $24.14M 10-Q · filed 2025-04-29 | |
| 2024-12-31 | $22.77M 10-K · filed 2026-02-26 | |
| 2024-09-30 | $33.69M 10-Q · filed 2024-11-18 | |
| 2024-06-30 | $34.04M 10-Q/A · filed 2024-11-18 | $36.30M 10-Q · filed 2024-07-30 |
| 2024-03-31 | $36.81M 10-Q/A · filed 2024-11-18 | $38.24M 10-Q · filed 2024-05-01 |
| 2023-12-31 | $39.32M 10-K · filed 2025-03-14 | $40.47M 10-K · filed 2024-02-22 |
| 2023-09-30 | $14.52M 10-Q/A · filed 2024-11-18 | $14.04M 10-Q · filed 2023-10-31 |
| 2023-06-30 | $22.04M 10-Q/A · filed 2024-11-18 | $21.90M 10-Q · filed 2023-08-02 |
| 2023-03-31 | $22.39M 10-Q/A · filed 2024-11-18 | $22.05M 10-Q · filed 2023-05-02 |
| 2022-12-31 | $23.00M 10-Q/A · filed 2024-11-18 | |
| 2022-09-30 | $23.41M 10-Q · filed 2022-11-01 | |
| 2022-06-30 | $23.65M 10-Q · filed 2022-08-02 | |
| 2022-03-31 | $25.86M 10-Q · filed 2022-04-27 | |
| 2021-12-31 | $33.48M 10-K · filed 2023-02-22 | |
| 2021-09-30 | $39.13M 10-Q · filed 2021-10-28 | |
| 2021-06-30 | $26.76M 10-Q · filed 2021-07-27 | |
| 2021-03-31 | $26.71M 10-Q · filed 2021-05-04 | |
| 2020-12-31 | $27.03M 10-K · filed 2022-02-17 | |
| 2020-09-30 | $29.43M 10-Q · filed 2020-11-05 | |
| 2020-06-30 | $29.95M 10-Q · filed 2020-07-30 | |
| 2019-12-31 | $29.94M 10-Q · filed 2020-11-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |